Fatigue News and Research

RSS

Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients

The second-generation proteasome inhibitor carfilzomib is showing noteworthy response rates and low levels of adverse side effects among multiple myeloma patients in a phase II clinical trial, researchers reported today at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Biogen Idec's BG-12 achieves key milestones in clinical trials for MS and RA

Biogen Idec today announced that its oral compound BG-12 (dimethyl fumarate) achieved key milestones in clinical trials for multiple sclerosis (MS) and rheumatoid arthritis (RA).

8 Dec 2009

Regular sexual activity can help improve the overall health in men

Boston Medical Group, a national physician network specializing in the treatment of erectile dysfunction and premature ejaculation, today released the top ten reasons regular sexual activity can help improve men’s overall health. From decreased blood pressure to more restful sleep, sexual activity is essential for maintaining bodily functions as well as overall health and well-being.

7 Dec 2009

CDC announces the start of National Influenza Vaccination Week

Today the Centers for Disease Control and Prevention (CDC) announced the start of National Influenza Vaccination Week. While the week was designed to highlight the importance of flu vaccinations, it also brings to light the importance of taking additional steps to keep you and your family healthy during the peak cold and flu season of December, January and beyond.

7 Dec 2009

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

Allos Therapeutics, Inc. today reported new analyses of data from the Company’s pivotal PROPEL trial of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

7 Dec 2009

Alexion Pharmaceuticals announces positive data from AEGIS study of Soliris

Alexion Pharmaceuticals, Inc. today announced positive data from the 26-week extension of the AEGIS study, an open-label registration study examining Soliris® (eculizumab) for the treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH).

7 Dec 2009

ImmunoGen reports encouraging clinical data of IMGN901

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today reported encouraging clinical data with its IMGN901 product candidate in the treatment of relapsed and relapsed/refractory multiple myeloma (MM), including prolonged benefit in patients whose disease had progressed on multiple prior treatment regimens.

6 Dec 2009

Deal time? Key Senate Dems meet on public option in health bill

Politico: "President Barack Obama will meet Sunday with Senate Democrats on Capitol Hill, as a group of moderate and liberal senators weighed a new public option compromise in hopes of striking a deal by early in the week.

6 Dec 2009

Positive final data from Phase 2 study of ISTODAX presented

Gloucester Pharmaceuticals announced today the presentation of positive final data from a Phase 2 study of ISTODAX® (romidepsin) in peripheral T-cell lymphoma (PTCL) conducted by the National Cancer Institute (NCI) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, LA.

6 Dec 2009

New treatment options for leukemia and myeloproliferative disorders introduced

Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology introduces potential new treatment options and improved diagnostic methods for patients suffering from acute promyelocytic leukemia, chronic myeloid leukemia, infant acute lymphoblastic leukemia, and myelofibrosis that are based on a better understanding of the underlying genetic causes of these conditions.

6 Dec 2009

FDA approves once-daily SEROQUEL XR Extended Release Tablets

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets as adjunctive (add-on) treatment to antidepressants in adults with Major Depressive Disorder (MDD).

4 Dec 2009

ARC workers protest that unfair labor practices can endanger donor and blood safety issues

Teamsters who work at American Red Cross (ARC) Blood Services facilities in Philadelphia went on strike this morning to protest unfair labor practices and problems with working conditions at these facilities that could imperil the safety of donors and the integrity of the blood supply, not to mention the wellbeing of employees.

3 Dec 2009

New approach to identify molecules that prevent immune cells from attacking body

A study led by a Scripps Research Institute scientist describes a new, highly pragmatic approach to the identification of molecules that prevent a specific type of immune cells from attacking their host. The findings add a powerful new tool to the ongoing search for potential treatments for autoimmune diseases, such as multiple sclerosis (MS), as well as blood cancers, such as myeloid leukemia.

2 Dec 2009

Study examines role of low-oxygen exposure in heart failure patients

Distance runners who live at high altitudes with low oxygen levels are known to improve their performance during races in areas that are at sea level. Can heart failure patients, who suffer from fatigue, improve their exercise performance by staying in a tent-like, high-altitude simulator?

1 Dec 2009

Eli Lilly's Cymbalta receives FDA approval

The U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, announced Eli Lilly and Company (NYSE: LLY).

30 Nov 2009

Chiropractic treatment for TMJ dysfunction

When most people hear the acronym TMJ, they think of their dentist. But a chiropractor can also give patients the help they need. TMJ stands for the Temporal-Mandibular Joint, which is where your jaw (mandible) contacts/connects with your skull (temporal bone).

26 Nov 2009

UT Southwestern Medical Center to offer NeuRx Diaphragm Pacing System implantation

Physicians at UT Southwestern Medical Center soon will begin implanting a new device designed to improve breathing in patients with upper spinal-cord injuries or other diseases that keep them from breathing independently.

26 Nov 2009

Myasthenia Gravis Alliance receives Global Pharmaceuticals grant to further research and awareness

Global Pharmaceuticals, the generic products division of Impax Laboratories, Inc., today announced their cooperation in awarding a modest grant to Myasthenia Gravis Alliance, also known as Myasthenia Gravis Foundation of Greater New York, Inc., a 501(3)(c) non profit membership corporation, incorporated in the State of New York.

25 Nov 2009

Ohr Pharmaceutical to develop OHR/AVR118 for cachexia treatment

Ohr Pharmaceutical Inc. is developing OHR/AVR118 for treatment of cachexia based on technology acquired earlier this year from Advanced Viral Research Corp. OHR/AVR118 has shown excellent therapeutic efficacy and safety in human clinical trials in over 100 patients with applications for cachexia in Cancer and AIDS patients, as well as Rheumatoid Arthritis.

24 Nov 2009

Withheld anger in MS patients can have adverse effect on health

People with Multiple Sclerosis (MS) feel more than twice as much withheld anger as the general population and this could have an adverse effect on their relationships and health, according to a study published in the December issue of the European Journal of Neurology.

24 Nov 2009